Imipramine Pamoate
6 NDCs across 2 manufacturers|6 Generic,0 Brand
Imipramine Pamoate is used to treat attention deficit disorder with hyperactivity, depressive disorder, enuresis, pain and panic disorder, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved before 1982, and the first generic was approved Apr 16, 2010. FDA's Orange Book lists 8 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $2 million on Imipramine Pamoate across 5,829 claims for 1,229 beneficiaries.
Imipramine Pamoate is available as 6 NDCs from 2 manufacturers (6 generic, 0 brand), with NADAC prices from $2.69 to $3.65 per EA — a 36% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
6
6G / 0B
Manufacturers
2
competing in market
Price Spread
$2.69 – $3.65
per EA
7d Activity
avg +0.6% WoW · of 6 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Hikma Pharmaceuticals USA Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Tricyclic Antidepressant class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
2 manufacturers producing IMIPRAMINE PAMOATE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
IMIPRAMINE PAMOATE 100 MG CAP | $3.6502 per EA | +3.80% |
IMIPRAMINE PAMOATE 100 MG CAP | $3.6502 per EA | +3.80% |
IMIPRAMINE PAMOATE 75 MG CAP | $3.2386 per EA | -1.63% |
IMIPRAMINE PAMOATE 75 MG CAP | $3.2386 per EA | -1.63% |
IMIPRAMINE PAMOATE 150 MG CAP | $2.6911 per EA | -0.45% |
IMIPRAMINE PAMOATE 150 MG CAP | $2.6911 per EA | -0.45% |
Frequently Asked Questions
What is Imipramine Pamoate used to treat?
Imipramine Pamoate is used to treat attention deficit disorder with hyperactivity, depressive disorder, enuresis, pain and panic disorder, per the National Library of Medicine's MED-RT classification.
When did Imipramine Pamoate become available as a generic?
FDA approved the first generic Imipramine Pamoate (ANDA) on Apr 16, 2010. The Orange Book currently lists 8 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Imipramine Pamoate?
In 2024, Medicare Part D spent $2 million on Imipramine Pamoate across 5,829 claims for 1,229 beneficiaries.
How many Imipramine Pamoate products are on the market?
The Imipramine Pamoate drug market contains 6 NDCs from 2 manufacturers — 6 generic and 0 brand products.
What is the price range for Imipramine Pamoate?
NADAC reference prices for Imipramine Pamoate range from $2.6911 to $3.6502 per EA — a 36% difference between cheapest and most expensive.
Which manufacturers make Imipramine Pamoate?
2 manufacturers list Imipramine Pamoate in NADAC. Ranked by number of NDCs, the largest are Hikma Pharmaceuticals USA Inc. (3), Lupin Pharmaceuticals Inc. (3).
How has the price of Imipramine Pamoate changed recently?
Over the past 7 days, 2 Imipramine Pamoate NDCs rose and 4 fell, with a market-wide average change of +0.6%.